Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00243243 |
|
Recruitment Status :
Completed
First Posted : October 21, 2005
Results First Posted : March 6, 2013
Last Update Posted : May 26, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Burns | Drug: Recombinant Factor VIIa Drug: Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 20 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Effect of Recombinant Coagulation Factor VIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn Excision and Grafting |
| Study Start Date : | January 2006 |
| Actual Primary Completion Date : | June 2011 |
| Actual Study Completion Date : | July 2011 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: rFVIIa
intravenous administration of rFVIIa (Novoseven; 90 micrograms/kg, IV push, given at start of first surgical incision and again at 1 hr after start of surgery)
|
Drug: Recombinant Factor VIIa
intravenous infusion of Factor VIIa |
|
Placebo Comparator: Control
intravenous administration of placebo (sterile water, IV push, given at first surgical incision and again at 1 hr after start of surgery)
|
Drug: Placebo
intravenous infusion of placebo (sterile water) |
- Total Number of Blood Components Transfused During and up to 24 Hours Post Operatively [ Time Frame: 24 hours ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female
- Burn wounds
- 18-65 years of age
- Scheduled excision of burn wound of at least 20 percent TBSA
Exclusion Criteria:
- Age greater than 65 years
- History of blood coagulation disorders
- Taking anti-coagulation medication
- Contraindication for heparin therapy
- Pregnant or nursing females
- Unstable angina
- MI within the last 6 months
- Recent of diagnosis of DVT, stroke within the last 6 months
- Renal failure requiring dialysis or creatinine clearance less than 25 ml/min
- Religious prohibition to blood transfusion
- Have received rFVIIa during current hospitalization
- Previous enrollment in this study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00243243
| United States, Texas | |
| United States Army Institute of Surgical Research | |
| Ft Sam Houston, Texas, United States, 78234 | |
| Principal Investigator: | Myung S Park, MD | United States Army Institute of Surgical Research |
| Responsible Party: | United States Army Institute of Surgical Research |
| ClinicalTrials.gov Identifier: | NCT00243243 |
| Other Study ID Numbers: |
H-05-027 |
| First Posted: | October 21, 2005 Key Record Dates |
| Results First Posted: | March 6, 2013 |
| Last Update Posted: | May 26, 2016 |
| Last Verified: | April 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
Burns |
|
Burns Wounds and Injuries |

